Dr. Coleman on FDA Approval of Relacorilant for Ovarian Cancer

The FDA-approved therapy relacorilant (Lifyorli) is offering a different approach for patients with platinum-resistant ovarian cancer, an area that has long needed new treatment options. Rather than targeting the tumor directly, this therapy works by blocking glucocorticoid receptor signaling, helping to restore the effectiveness of chemotherapy and giving clinicians a meaningful new tool in a historically difficult treatment setting.

Glucocorticoids are commonly used to manage chemotherapy side effects, but research has revealed that they may also interfere with how chemotherapy induces cancer cell death. When glucocorticoid receptor signaling is activated, it can reduce the apoptotic response that chemotherapy relies on to eliminate cancer cells. By inhibiting this pathway, the new combination approach allows treatment to work more effectively, promoting apoptosis and improving overall outcomes for patients who have few remaining options.

Importantly, this therapy does not require biomarker testing, making it a potential option for a broader range of patients regardless of their molecular profile. This is a meaningful distinction in oncology, where many targeted therapies are limited to specific patient subgroups. Its flexibility also allows clinicians to consider it across multiple lines of treatment depending on individual patient needs, prior therapies, and treatment history.

In the discussion, Robert Coleman, MD, a gynecologic oncologist at Texas Oncology and the codirector of the Gynecologic Oncology Group, explains the science behind glucocorticoid receptor signaling, how this approach fits into current clinical practice, and what it means for day-to-day patient care. She also addresses practical considerations for integrating this therapy into existing treatment plans.

Clinical data show meaningful improvements compared to historical chemotherapy options, including an approximately 30% reduction in the risk of disease progression. There are also early indications of improved overall survival, marking a significant step forward in the treatment landscape for platinum-resistant ovarian cancer.

As research continues to evolve and longer-term data emerge, this new therapy represents a promising advancement—offering patients more time on effective treatment, preserved quality of life, and renewed hope in a challenging and often devastating disease setting.